Charles River Laboratories International (CRL) has completed the previously announced acquisition of the CRO services division of Galapagos (GLPGF), which includes both Argenta and BioFocus.
The global healthcare personal protective equipment market size was valued at USD 22.96 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% from 2020 to 2028
A recent study published in the British Journal of Nutrition reveals promising results regarding the use of daily prebiotic fiber supplements in patients
with pre-diabetes, suggesting significant improvements in insulin sensitivity and other vital health markers.
"Pre-diabetes affects over 7 million individuals in the UK," says Dr. Thomas Gurry, CEO at myota. "Our findings have shown that prebiotic fiber represents a
promising and efficacious fast-acting treatment to manage pre-diabetes."
Conducted over 24 weeks with 66 prediabetic participants, the study, led by scientists from myota and CRO Lindus Health, utilised a diverse prebiotic blend.
"The results of our study suggest that this natural diverse prebiotic fiber supplement could be taken to reverse pre-diabetes and to prevent or slow the onset
of type 2 diabetes," says Dr. Caitlin Hall, Head of Research at myota.